297 related articles for article (PubMed ID: 23893554)
1. Outcomes after primary chemoradiotherapy for N3 (>6 cm) head and neck squamous cell carcinoma after an FDG-PET--guided neck management policy.
Adams G; Porceddu SV; Pryor DI; Panizza B; Foote M; Rowan A; Burmeister B
Head Neck; 2014 Aug; 36(8):1200-6. PubMed ID: 23893554
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of positron emission tomography-directed management of the neck in node-positive head and neck cancer after organ preservation therapy.
Sjövall J; Chua B; Pryor D; Burmeister E; Foote MC; Panizza B; Burmeister BH; Porceddu SV
Oral Oncol; 2015 Mar; 51(3):260-6. PubMed ID: 25553622
[TBL] [Abstract][Full Text] [Related]
3. Therapy Response Assessment and Patient Outcomes in Head and Neck Squamous Cell Carcinoma: FDG PET Hopkins Criteria Versus Residual Neck Node Size and Morphologic Features.
Wray R; Sheikhbahaei S; Marcus C; Zan E; Ferraro R; Rahmim A; Subramaniam RM
AJR Am J Roentgenol; 2016 Sep; 207(3):641-7. PubMed ID: 27341273
[TBL] [Abstract][Full Text] [Related]
4. The role of CT and ¹⁸F-FDG PET in managing the neck in node-positive head and neck cancer after chemoradiotherapy.
Inohara H; Enomoto K; Tomiyama Y; Yoshii T; Osaki Y; Higuchi I; Inoue T; Hatazawa J
Acta Otolaryngol; 2009 Aug; 129(8):893-9. PubMed ID: 18839385
[TBL] [Abstract][Full Text] [Related]
5. The role of changes in maximum standardized uptake value of FDG PET-CT for post-treatment surveillance in patients with head and neck squamous cell carcinoma treated with chemoradiotherapy: preliminary findings.
Matoba M; Tuji H; Shimode Y; Kondo T; Oota K; Tonami H
Br J Radiol; 2017 Mar; 90(1071):20150404. PubMed ID: 28055245
[TBL] [Abstract][Full Text] [Related]
6. Economic analysis of FDG-PET-guided management of the neck after primary chemoradiotherapy for node-positive head and neck squamous cell carcinoma.
Pryor DI; Porceddu SV; Scuffham PA; Whitty JA; Thomas PA; Burmeister BH
Head Neck; 2013 Sep; 35(9):1287-94. PubMed ID: 22987817
[TBL] [Abstract][Full Text] [Related]
7. Assessment of outcomes with delayed (18)F-FDG PET-CT response assessment in head and neck squamous cell carcinoma.
Slevin F; Subesinghe M; Ramasamy S; Sen M; Scarsbrook AF; Prestwich RJ
Br J Radiol; 2015 Aug; 88(1052):20140592. PubMed ID: 26081447
[TBL] [Abstract][Full Text] [Related]
8. Neck dissection can be avoided after sequential chemoradiotherapy and negative post-treatment positron emission tomography-computed tomography in N2 head and neck squamous cell carcinoma.
Loo SW; Geropantas K; Beadsmoore C; Montgomery PQ; Martin WM; Roques TW
Clin Oncol (R Coll Radiol); 2011 Oct; 23(8):512-7. PubMed ID: 21501953
[TBL] [Abstract][Full Text] [Related]
9. PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer.
Mehanna H; McConkey CC; Rahman JK; Wong WL; Smith AF; Nutting C; Hartley AG; Hall P; Hulme C; Patel DK; Zeidler SV; Robinson M; Sanghera B; Fresco L; Dunn JA
Health Technol Assess; 2017 Apr; 21(17):1-122. PubMed ID: 28409743
[TBL] [Abstract][Full Text] [Related]
10. The role of positron emission tomography scans in the management of the N-positive neck in head and neck squamous cell carcinoma after chemoradiotherapy.
Brkovich VS; Miller FR; Karnad AB; Hussey DH; McGuff HS; Otto RA
Laryngoscope; 2006 Jun; 116(6):855-8. PubMed ID: 16735902
[TBL] [Abstract][Full Text] [Related]
11. Imaging strategy for response evaluation to chemoradiotherapy of the nodal disease in patients with head and neck squamous cell carcinoma.
Nishimura G; Yabuki K; Hata M; Komatsu M; Taguchi T; Takahashi M; Shiono O; Sano D; Arai Y; Takahashi H; Chiba Y; Oridate N
Int J Clin Oncol; 2016 Aug; 21(4):658-667. PubMed ID: 26710795
[TBL] [Abstract][Full Text] [Related]
12. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment.
Yao M; Smith RB; Graham MM; Hoffman HT; Tan H; Funk GF; Graham SM; Chang K; Dornfeld KJ; Menda Y; Buatti JM
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):991-9. PubMed ID: 16099601
[TBL] [Abstract][Full Text] [Related]
13. Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy.
Tan A; Adelstein DJ; Rybicki LA; Saxton JP; Esclamado RM; Wood BG; Lorenz RR; Strome M; Carroll MA
Arch Otolaryngol Head Neck Surg; 2007 May; 133(5):435-40. PubMed ID: 17515501
[TBL] [Abstract][Full Text] [Related]
14. Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy.
Porceddu SV; Pryor DI; Burmeister E; Burmeister BH; Poulsen MG; Foote MC; Panizza B; Coman S; McFarlane D; Coman W
Head Neck; 2011 Dec; 33(12):1675-82. PubMed ID: 22076976
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of quantitative diffusion-weighted imaging and 18-F-FDG-PET in head and neck squamous cell carcinoma treated by (chemo)radiotherapy.
Martens RM; Noij DP; Koopman T; Zwezerijnen B; Heymans M; de Jong MC; Hoekstra OS; Vergeer MR; de Bree R; Leemans CR; de Graaf P; Boellaard R; Castelijns JA
Eur J Radiol; 2019 Apr; 113():39-50. PubMed ID: 30927958
[TBL] [Abstract][Full Text] [Related]
16. Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT.
Nayak JV; Walvekar RR; Andrade RS; Daamen N; Lai SY; Argiris A; Smith RP; Heron DE; Ferris RL; Johnson JT; Branstetter BF
Laryngoscope; 2007 Dec; 117(12):2129-34. PubMed ID: 17921898
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer.
McCollum AD; Burrell SC; Haddad RI; Norris CM; Tishler RB; Case MA; Posner MR; Van den Abbeele AD
Head Neck; 2004 Oct; 26(10):890-6. PubMed ID: 15390197
[TBL] [Abstract][Full Text] [Related]
18. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
[TBL] [Abstract][Full Text] [Related]
19. Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST.
Katsuura T; Kitajima K; Fujiwara M; Terada T; Uwa N; Noguchi K; Doi H; Tamaki Y; Yoshida R; Tsuchitani T; Fujita M; Yamakado K
Ann Nucl Med; 2018 Aug; 32(7):453-462. PubMed ID: 29858797
[TBL] [Abstract][Full Text] [Related]
20. Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection.
Karakaya E; Yetmen O; Oksuz DC; Dyker KE; Coyle C; Sen M; Prestwich RJ
Oral Oncol; 2013 Jan; 49(1):55-9. PubMed ID: 22858313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
